Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 826

Sort by

Sort Order Select

Journal Articles

bcr3 PML-RARA : short fusion, small blasts!

Moe R. Takeda, Sandeep Gurbuxani

Blood (2021) 137 (19): 2708.

https://doi.org/10.1182/blood.2021010965

Published: 2021

Journal Articles

PML-RARα: changing myeloid networks

Scott C. Kogan

Blood (2021) 137 (11): 1439–1440.

https://doi.org/10.1182/blood.2020008849

Published: 2021

Journal Articles

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Yun Tan, Xiaoling Wang, Huan Song, Yi Zhang, Rongsheng Zhang, Shufen Li, Wen Jin, Saijuan Chen, Hai Fang, Zhu Chen, Kankan Wang

Blood (2021) 137 (11): 1503–1516.

https://doi.org/10.1182/blood.2020005698

Published: 2021

Includes: Supplemental data

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

Gata2 Expression and Function in PML-RARA- driven Preleukemia and APL

Casey D.S. Katerndahl, PhD, Timothy J Ley, MD, Michelle A Cai, Timothy P Rooney, Jr., Sai Mukund Ramakrishnan, MS, Sridhar Nonavinkere Srivatsan, MS, Christopher A Miller, PhD

Blood (2019) 134 (Supplement_1): 534.

https://doi.org/10.1182/blood-2019-131883

Published: 2019

Journal Articles

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Hassan Awada, MD, Jibran Durrani, Tariq Zuheir Kewan, MD, Ashwin Kishtagari, MBBS, Valeria Visconte, PhD, Reda Z. Mahfouz, MD PhD

Blood (2019) 134 (Supplement_1): 1404.

https://doi.org/10.1182/blood-2019-131724

Published: 2019

Journal Articles

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Alison J. Moskowitz, MD, Heiko Schoder, MD, Jisun Lee, Theresa Davey, MMSc, PA-C, Helen Hancock, ANP, Paul A. Hamlin, MD, Steven M. Horwitz, MD, Anita Kumar, MD, Matthew J Matasar, MD, Ariela Noy, MD, M. Lia Palomba, MD, Gunjan L. Shah, MDMS, Miguel-Angel Perales, MD, Craig S. Sauter, MD, David J. Straus, MD, Anas Younes, MD, Andrew D. Zelenetz, MD PhD, Joachim Yahalom, MD, Craig H. Moskowitz

Blood (2019) 134 (Supplement_1): 1555.

https://doi.org/10.1182/blood-2019-129364

Published: 2019

Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, MD, Bruce D. Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, MD, Uwe H Hahn, MD, Eliza A Hawkes, Cyrus Khan, MD, Izidore S. Lossos, MD, Gerardo Musuraca, MD PhD, Monica Tani, Umberto Vitolo, Sam Lung Sang Yuen, MBBS,FRCPA,FRACP, Aparna Raval, PhD, Mahesh R. Shivhare, PhD, Tina G Nielsen, MD PhD, Gila Sellam, PhD, Jeff P. Sharman, MD

Blood (2019) 134 (Supplement_1): 2874.

https://doi.org/10.1182/blood-2019-123368

Published: 2019

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Judah Friedman, MD, Hun Ju Lee, MD, Linda Ho, Ian W. Flinn, MD PhD

Blood (2019) 134 (Supplement_1): 2836.

https://doi.org/10.1182/blood-2019-122969

Published: 2019

Journal Articles

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

Jorge Monge, MD, Jorge Contreras, MD, Sarah Elsoukkary, MD, Jin Guo, MD, Art Perry, PA, Robin S. Solomon, Kari Flicker, BS, David S Jayabalan, MSc, Morton Coleman, MD, Adriana C. Rossi, MDMSc, Rebecca Harris, MD, Markus Plate, MD, Joerg-Patrick Stuebgen, MB, ChB, MD, Ruben Niesvizky, MD

Blood (2019) 134 (Supplement_1): 4876.

https://doi.org/10.1182/blood-2019-122134

Published: 2019

Journal Articles

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Fernanda Marconi Roversi, Maura Lima Pereira Bueno, undergraduate, Cristiane Okuda Torello, PhD, Fernanda I Della Via, MSc, Renata Giardini Rosa, PhD, Juares Ednaldo Romero Bianco, PhD, Adriana Silva Santos Duarte, PhD, Eduardo M Rego, MD PhD, Alessio Molinari, Maurizio Botta, Sara T Olalla Saad, PhD

Blood (2019) 134 (Supplement_1): 4650.

https://doi.org/10.1182/blood-2019-128959

Published: 2019

Journal Articles

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Anna Stengel, PhD, Rabia Shahswar, MD, Wencke Walter, PhD, Manja Meggendorfer, PhD, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2019) 134 (Supplement_1): 887.

https://doi.org/10.1182/blood-2019-124310

Published: 2019

Journal Articles

Untangling the Transcriptional Mis-Regulation Driven By Pml;rara

William Villiers, MSc, Paul Lavender, PhD, Audrey Kelly, PhD, Michael Lim, MD PhD, Cameron Osborne, PhD, Richard Dillon, MA, PhD MRCP, FRCPath

Blood (2019) 134 (Supplement_1): 282.

https://doi.org/10.1182/blood-2019-125555

Published: 2019

Journal Articles

PML Plays a Key Role in Severe Congenital Neutropenia with Mutant ELANE Causing Neutrophil Elastase Protein Misfolding

Patricia Olofsen, MSc, Paulette van Strien, BSc, Onno Roovers, BSc, Hans De Looper, BSc, Remco Hoogenboezem, MSc, Dennis Bosch, BSc, Mehrnaz Ghazvini, PhD, Eric Bindels, PhD, Emma De Pater, PhD, Ivo Touw, PhD

Blood (2019) 134 (Supplement_1): 213.

https://doi.org/10.1182/blood-2019-122423

Published: 2019

Journal Articles

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

Yoo Jin Lee, MD PhD, Seo-Yeon Ahn, MD, Jae-Cheol Jo, MD PhD, Yunsuk Choi, MD, Ji Hyun Lee, MD PhD

Blood (2019) 134 (Supplement_1): 3898.

https://doi.org/10.1182/blood-2019-125671

Published: 2019

Journal Articles

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

Mathilde Poplineau, Nadine Platet, PhD, Lia N'Guyen, Shuhei Koide, PhD, Julien Vernerey, PhD, Yaeko Nakajima-Takagi, PhD, Motohiko Oshima, PhD, Atsushi Iwama, MD PhD, Estelle Duprez, PhD

Blood (2019) 134 (Supplement_1): 3761.

https://doi.org/10.1182/blood-2019-125509

Published: 2019

Journal Articles

Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO

Jorge Cortes, MD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Nicholas J. Short, MD, Yesid Alvarado, MD, Musa E. Yilmaz, MD, Naval G. Daver, MD, David McCue, Sherry A. Pierce, BSN, BA, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2019) 134 (Supplement_1): 3851.

https://doi.org/10.1182/blood-2019-124599

Published: 2019

Journal Articles

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Harinder Gill, FRCP, FRCPath, Rita Yim, PhD, Cyrus R Kumana, FRCP, Yok-Lam Kwong, MD

Blood (2019) 134 (Supplement_1): 3853.

https://doi.org/10.1182/blood-2019-125185

Published: 2019

Journal Articles

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

Isabel Weinhäuser, MSc, Diego A Pereira-Martins, MSc, Luíse A A Simões, BSc, César Alexander Ortiz Rojas, BSc, Thiago Mantello Bianco, MSc, Cleide Lucia Silva, MSc, Mariane Cristina Do Nascimento, BSc, Lorena Lobo Figueiredo-Pontes, MD PhD, Antonio R. Lucena-Araujo, PhD, Eduardo M Rego, MD PhD

Blood (2019) 134 (Supplement_1): 5165.

https://doi.org/10.1182/blood-2019-131496

Published: 2019

Journal Articles

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Olga Kulemina, MD, Nadia Siordia, MD, Konstantin Bogdanov, PhD, Julia Alexeeva, MD PhD, Larisa Girshova, MD PhD, Elza Lomaia, MD PhD, Andrey Zaritskey, MD PhD

Blood (2019) 134 (Supplement_1): 5138.

https://doi.org/10.1182/blood-2019-129815

Published: 2019

NARROW

bcr3 PML-RARA : short fusion, small blasts!

PML-RARα: changing myeloid networks

A PML/RARα direct target atlas redefines transcriptional deregulation in acute promyelocytic leukemia

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Gata2 Expression and Function in PML-RARA- driven Preleukemia and APL

Comprehensive Characterization of Cytogenetic and Mutational Analysis of Acute Promyelocytic Leukemia: Is PML-Rara Everything?

Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analysis of a Phase I/II Study

Brentuximab Vedotin in Combination with Nivolumab, Doxorubucin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma

Progressive Multifocal Leukoencephalopathy in a Patient with Multiple Myeloma Receiving Daratumumab and Pomalidomide

A Novel Chemical Compound Inhibiting Hematopoietic Cell Kinase (iHCK) Has a Synergic Effect with Azacytidine (Aza) or Cytarabine (Ara-C) for Acute Myeloid Leukemia Treatment

Application of RNA Sequencing Detects a Large Number of Novel Fusion Transcripts in Patients with AML and MDS

Untangling the Transcriptional Mis-Regulation Driven By Pml;rara

PML Plays a Key Role in Severe Congenital Neutropenia with Mutant ELANE Causing Neutrophil Elastase Protein Misfolding

Efficacy and Safety of Daily All-Trans Retinoic Acid Monotherapy As Maintenance Therapy for Acute Promyelocytic Leukemia

New Insights into PLZF/Rara Mechanism during APL Onset: EZH2 on the Road

Value of Minimal Residual Disease (MRD) Monitoring Using Real-Time Quantitative PCR in Patients with Acute Promyelocytic Leukemia (APL) Treated with ATRA, ATO, +/- GO

Oral Arsenic Trioxide, ATRA and Ascorbic Acid (AAA) Maintenance Following First Complete Remission in Acute Promyelocytic Leukemia - Long-Term Data and Unique Prognostic Indicators

Reduced SLIT2 Are Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in APL Cells

BCR-ABL1+ AML De Novo and CBF-Leukemia at Relapse: Game of Clones

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only